AU Patent

AU2016426574B2 — Hodgkin lymphoma therapy

Assigned to Euro Celtique SA · Expires 2023-07-13 · 3y expired

What this patent protects

There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically …

USPTO Abstract

There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: I, a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotinand said combination for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said combination.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016426574B2
Jurisdiction
AU
Classification
—
Expires
2023-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Euro Celtique SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.